237 related articles for article (PubMed ID: 22184762)
1. Economic burden of dermatologic adverse events induced by molecularly targeted cancer agents.
Borovicka JH; Calahan C; Gandhi M; Abraham TS; Kwasny MJ; Haley AC; West DP; Lacouture ME
Arch Dermatol; 2011 Dec; 147(12):1403-9. PubMed ID: 22184762
[TBL] [Abstract][Full Text] [Related]
2. Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic.
Rosen AC; Case EC; Dusza SW; Balagula Y; Gordon J; West DP; Lacouture ME
Am J Clin Dermatol; 2013 Aug; 14(4):327-33. PubMed ID: 23625802
[TBL] [Abstract][Full Text] [Related]
3. Outpatient cancer drug costs: changes, drivers, and the future.
Halbert RJ; Zaher C; Wade S; Malin J; Lawless GD; Dubois RW
Cancer; 2002 Feb; 94(4):1142-50. PubMed ID: 11920485
[TBL] [Abstract][Full Text] [Related]
4. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center.
Nonzee NJ; Dandade NA; Patel U; Markossian T; Agulnik M; Argiris A; Patel JD; Kern RC; Munshi HG; Calhoun EA; Bennett CL
Cancer; 2008 Sep; 113(6):1446-52. PubMed ID: 18683883
[TBL] [Abstract][Full Text] [Related]
6. Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Autier J; Escudier B; Wechsler J; Spatz A; Robert C
Arch Dermatol; 2008 Jul; 144(7):886-92. PubMed ID: 18645140
[TBL] [Abstract][Full Text] [Related]
7. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis.
Ghatnekar O; Alvegård T; Conradi N; Lenhoff S; Mellqvist UH; Persson U; Löthgren M
Clin Ther; 2008 Sep; 30(9):1704-13. PubMed ID: 18840377
[TBL] [Abstract][Full Text] [Related]
8. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
9. Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China.
Wang G; Cheng Q; Zheng R; Tan YY; Sun XK; Zhou HY; Ye XL; Wang Y; Wang Z; Sun BM; Chen SD
Mov Disord; 2006 Sep; 21(9):1439-43. PubMed ID: 16773620
[TBL] [Abstract][Full Text] [Related]
10. Health care expenditures and therapeutic outcomes of a pharmacist-managed anticoagulation service versus usual medical care.
Hall D; Buchanan J; Helms B; Eberts M; Mark S; Manolis C; Peele P; Docimo A
Pharmacotherapy; 2011 Jul; 31(7):686-94. PubMed ID: 21923456
[TBL] [Abstract][Full Text] [Related]
11. Examining the utility of in-clinic "rescue" therapy for acute migraine.
Morey V; Rothrock JF
Headache; 2008 Jun; 48(6):939-43. PubMed ID: 18549372
[TBL] [Abstract][Full Text] [Related]
12. Economic burden of rhinitis in managed care: a retrospective claims data analysis.
Dalal AA; Stanford R; Henry H; Borah B
Ann Allergy Asthma Immunol; 2008 Jul; 101(1):23-9. PubMed ID: 18681080
[TBL] [Abstract][Full Text] [Related]
13. American Society of Clinical Oncology guidance statement: the cost of cancer care.
Meropol NJ; Schrag D; Smith TJ; Mulvey TM; Langdon RM; Blum D; Ubel PA; Schnipper LE;
J Clin Oncol; 2009 Aug; 27(23):3868-74. PubMed ID: 19581533
[TBL] [Abstract][Full Text] [Related]
14. Costs associated with attempted suicide among individuals with bipolar disorder.
Stensland MD; Zhu B; Ascher-Svanum H; Ball DE
J Ment Health Policy Econ; 2010 Jun; 13(2):87-92. PubMed ID: 20919595
[TBL] [Abstract][Full Text] [Related]
15. Availability and affordability of anticancer medicines at the Ocean Road Cancer Institute in Dar es Salaam, Tanzania.
Yohana E; Kamuhabwa A; Mujinja P
East Afr J Public Health; 2011 Mar; 8(1):52-7. PubMed ID: 22066285
[TBL] [Abstract][Full Text] [Related]
16. [Managing cutaneous toxicities of targeted therapies].
Kiyohara Y
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1597-602. PubMed ID: 23152009
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination.
Townsley CA; Pond GR; Oza AM; Hirte HW; Winquist E; Goss G; Degendorfer P; Moore MJ; Siu LL
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2141-9. PubMed ID: 16609027
[TBL] [Abstract][Full Text] [Related]
18. Costing substance misuse services.
Coyle D; Godfrey C; Hardman G; Raistrick D
Addiction; 1997 Aug; 92(8):1007-15. PubMed ID: 9376770
[TBL] [Abstract][Full Text] [Related]
19. The mounting medical care cost for adult AIDS patients at the Faculty of Medicine, Siriraj Hospital: consideration for management.
Suwanagool S; Ratanasuwan W; Techasathit W
J Med Assoc Thai; 1997 Jul; 80(7):431-9. PubMed ID: 9277072
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of resected squamous cell carcinoma of the head and neck in a US managed-care population.
Amonkar MM; Chastek B; Samant N; Teitelbaum A
J Med Econ; 2011; 14(4):421-32. PubMed ID: 21619455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
